Israel Englander Fibrogen Inc Transaction History

Millennium Management LLC

$192 Billion
Q4 2024

A detailed history of Israel Englander (Millennium Management LLC) transactions in Fibrogen Inc stock. As of the latest transaction made, Millennium Management LLC holds 830,605 shares of FGEN stock, worth $465,138. This represents 0.0% of its overall portfolio holdings.

Number of Shares

830,605

Previous 964,959 13.92%

Holding current value

$465,138

Previous $385,000 14.29%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$0.3 - $0.58 $40,306 - $77,925	-134,354 Reduced 13.92%	830,605 $440,000
Q3 2024 Nov 14, 2024	SELL	$0.33 - $1.26 $375,756 - $1.43 Million	-1,138,655 Reduced 54.13%	964,959 $385,000
Q2 2024 Aug 14, 2024	BUY	$0.89 - $2.36 $1.77 Million - $4.69 Million	1,987,364 Added 1709.56%	2,103,614 $1.87 Million
Q1 2024 May 15, 2024	SELL	$0.73 - $2.73 $358,546 - $1.34 Million	-491,159 Reduced 80.86%	116,250 $273,000
Q4 2023 Feb 14, 2024	SELL	$0.38 - $0.91 $1.06 Million - $2.55 Million	-2,800,988 Reduced 82.18%	607,409 $540,000
Q2 2023 Aug 14, 2023	BUY	$2.49 - $20.59 $7 Million - $57.9 Million	2,810,468 Added 470.03%	3,408,397 $9.2 Million
Q1 2023 May 15, 2023	BUY	$15.95 - $25.18 $6.73 Million - $10.6 Million	421,729 Added 239.35%	597,929 $11.2 Million
Q4 2022 Feb 14, 2023	BUY	$13.27 - $17.73 $1.93 Million - $2.58 Million	145,630 Added 476.38%	176,200 $2.82 Million
Q3 2022 Nov 14, 2022	SELL	$11.4 - $14.6 $663,776 - $850,099	-58,226 Reduced 65.57%	30,570 $398,000
Q2 2022 Aug 15, 2022	BUY	$7.94 - $12.96 $602,669 - $983,702	75,903 Added 588.71%	88,796 $938,000
Q1 2022 May 16, 2022	SELL	$12.02 - $16.79 $1.38 Million - $1.93 Million	-114,837 Reduced 89.91%	12,893 $155,000
Q4 2021 Feb 14, 2022	SELL	$9.93 - $15.39 $5.85 Million - $9.07 Million	-589,577 Reduced 82.19%	127,730 $1.8 Million
Q3 2021 Nov 15, 2021	BUY	$10.18 - $26.64 $7.19 Million - $18.8 Million	705,827 Added 6148.32%	717,307 $7.33 Million
Q2 2021 Aug 16, 2021	BUY	$18.57 - $35.68 $70,807 - $136,047	3,813 Added 49.73%	11,480 $306,000
Q1 2021 May 17, 2021	SELL	$31.0 - $55.72 $1.47 Million - $2.63 Million	-47,262 Reduced 86.04%	7,667 $266,000
Q4 2020 Feb 16, 2021	BUY	$37.09 - $48.97 $1.71 Million - $2.25 Million	46,006 Added 515.59%	54,929 $2.04 Million
Q3 2020 Nov 16, 2020	SELL	$40.47 - $45.5 $6.55 Million - $7.37 Million	-161,894 Reduced 94.78%	8,923 $367,000
Q2 2020 Aug 14, 2020	BUY	$32.57 - $42.83 $2.43 Million - $3.2 Million	74,713 Added 77.74%	170,817 $6.92 Million
Q1 2020 May 14, 2020	BUY	$23.3 - $45.96 $2.11 Million - $4.16 Million	90,617 Added 1651.49%	96,104 $3.34 Million
Q4 2019 Feb 14, 2020	SELL	$34.58 - $48.06 $1.81 Million - $2.51 Million	-52,275 Reduced 90.5%	5,487 $235,000
Q3 2019 Nov 14, 2019	BUY	$36.98 - $48.45 $2.14 Million - $2.8 Million	57,762 New	57,762 $2.14 Million
Q2 2019 Aug 14, 2019	SELL	$35.13 - $55.53 $5.88 Million - $9.29 Million	-167,368 Closed	0 $0
Q1 2019 May 14, 2019	BUY	$42.83 - $59.91 $6.92 Million - $9.69 Million	161,667 Added 2835.77%	167,368 $9.1 Million
Q4 2018 Feb 14, 2019	SELL	$37.97 - $60.16 $3.83 Million - $6.07 Million	-100,893 Reduced 94.65%	5,701 $264,000
Q3 2018 Nov 14, 2018	BUY	$56.3 - $67.25 $5.3 Million - $6.33 Million	94,056 Added 750.17%	106,594 $6.48 Million
Q2 2018 Aug 14, 2018	SELL	$44.9 - $64.95 $3.96 Million - $5.73 Million	-88,221 Reduced 87.56%	12,538 $785,000
Q1 2018 May 15, 2018	BUY	$45.35 - $61.65 $3.78 Million - $5.14 Million	83,404 Added 480.58%	100,759 $4.66 Million
Q4 2017 Feb 14, 2018	BUY	$41.95 - $60.1 $728,042 - $1.04 Million	17,355	17,355 $823,000

Others Institutions Holding FGEN

# of Institutions

Shares Held

37.4M

Call Options Held

351K

Put Options Held

105K

View Full List

About FIBROGEN INC

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $52.5M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

More about FGEN

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account